87 results about "Non diabetic" patented technology

A method for collecting optical data at two morphologically similar, substantially non-overlapping, and preferably adjacent, areas on the surface of a tissue, while the temperature in each area is being maintained or modulated according to a temperature program. The optical data obtained are inserted into a mathematical relationship, e.g., an algorithm, that can be used to predict a disease state (such as the diabetes mellitus disease state) or the concentration of an analyte for indicating a physical condition (such as blood glucose level). This invention can be used to differentiate between disease status, such as, for example, diabetic and non-diabetic. The method involves the generation of a calibration (or training) set that utilizes the relationship between optical signals emanating from the skin under different thermal stimuli and disease status, e.g., diabetic status, established clinically. This calibration set can be used to predict the disease state of other subjects. Structural changes, as well as circulatory changes, due to a disease state are determined at two morphologically similar, but substantially non-overlapping areas on the surface of human tissue, e.g., the skin of a forearm, with each area being subjected to different temperature modulation programs. In addition to determination of a disease state, this invention can also be used to determine the concentration of an analyte in the tissues. This invention also provides an apparatus for the determination of a disease state, such as diabetes, or concentration of an analyte, such as blood glucose level, by the method of this invention.

New optical coherence tomography (OCT) techniques are disclosed which are designed to improve OCT glucose concentration measure accuracy and are capable of being performed on a continuous basis. New multi-wavelength optical coherence tomography (OCT) techniques are also disclosed and designed to reduce artifacts do to water. New optical coherence tomography (OCT) techniques are also disclosed for determining local profusion rates, local analyte transport rates and tissue analyte transport rates as a measure of tissue health, disease progression and state and tissue transplantation effectiveness.

The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.

Apparatus and methods for spectroscopic analysis of human tissue to classify an individual as diabetic or non-diabetic, or to determine the probability, progression or level of diabetes in an individual. Tissue optical information of an individual, including at least a measurement of at least one wavelength or group of wavelengths indicative of glycosylated collagen content in tissue, is analyzed using multivariate techniques. The multivariate techniques include an algorithm developed from optical information from individuals having a known disease state. At least one factor in the algorithm is dependent on or a function of the measurement of the at least one wavelength or group of wavelengths indicative of glycosylated collagen content in tissue from the optical information of individuals forming the database.

Provided are systems and methods using which users may learn and become familiar with the effects of various aspects of their lifestyle on their health, e.g., users may learn about how food and/or exercise affects their glucose level and other physiological parameters, as well as overall health. In some cases the user selects a program to try; in other cases, a computing environment embodying the system suggests programs to try, including on the basis of pattern recognition, i.e., by the computing environment determining how a user could improve a detected pattern in some way. In this way, users such as type II diabetics or even users who are only prediabetic or non-diabetic may learn healthy habits to benefit their health.

A formulation of phenyloin suitable for topical application to a wound comprises a reservoir of phenyloin entrapped within a stabilising matrix, and an amount of dissolved phenyloin, wherein the dissolved phenyloin is in chemical equilibrium with the phenyloin entrapped within the stabilised matrix. The stabilised matrix may comprise a gel matrix, especially a gel matrix in which the polymer of the gel forms ion-pairs with the phenyloin. Also described are methods of treating a wound in diabetic and non-diabetic patients using a formulation according to the invention.

Provided are methods for determining concurrently with a simple, minimally invasive test, the adequacy of pancreatic beta-cell compensation and/or the presence of tissue insulin resistance in a subject human or an experimental animal. The methods allow for the determination of a subject's or experimental animal's susceptibility to developing type 2 diabetes mellitus (DM2) or to progression to more advanced forms of DM2. Among other uses, the methods allow for diagnostic classification of subjects for decisions regarding therapeutic interventions, clinical differentiation between type 1 DM and DM2, clinical monitoring of treatments intended to reduce risk of developing DM2 in non-diabetic subjects, clinical monitoring of agents intended to improve existing DM2 and to prevent progression of DM2, clinical development and testing of new compounds, candidate agents, or candidate therapies for preventing progression to DM2 or disease progression in existing DM2, and preclinical screening of candidate agents or candidate therapies in experimental animals to identify and characterize agents having insulin-sensitizing properties, pancreatic stimulatory or regenerative properties or other desirable actions.

A method of promoting bone healing in a non-diabetic patient in need thereof by locally administering a therapeutically effective amount of insulin to the patient. A drug delivery device, which includes insulin and a pharmaceutically acceptable carrier, wherein the device is adapted for localized administration of insulin to a patient in need thereof is also presented.

Described is use of Salvia hispanica L. (Chia) for controlling, in one embodiment reducing, blood glucose levels, preferably post-prandial blood glucose levels. This is useful in both non-diabetic and diabetic individuals, but especially in diabetic individuals. Also described is the use of chia in reducing postprandial blood glucose, insulin sensitivity, blood pressure, and oxidative stress in such individuals. The present invention further found that Chia can be used to improve endothelial function, coagulation, fibrinolysis and iron status. The present invention further encompasses the use of Chia in the treatment and/or management of diabetes and/or the treatment and management of diabetes associated conditions or risk factors, such as one or more of the following: blood pressure and blood glucose levels, post-prandial glycemia, inflammatory factors (C-reactive protein), coagulation (fibrinogen, factor VIII, von Willenbrand factor), and fibronolytic factors (such as t-PA), iron status and endothelial function, (such as increase in nitric oxide generation). In one embodiment the invention relates to dietary approaches to such treatment and management.

Disclosed are methods of producing a blunted postprandial glycemic response in an individual, and/or reducing postprandial insulin secretion, said methods comprising administering to the individual a nutritional or other product comprising gamma-cyclodextrin. Also disclosed are similar other methods directed toward the use of such products to provide weight and appetite control, to normalize blood glucose levels in individuals with impaired glucose tolerance, to minimize nighttime hypoglycemia in diabetic and non-diabetic patients, to prevent reactive hypoglycemia in susceptible non-diabetics, to normalize blood glucose levels in individuals with gestational diabetes or impaired glucose tolerance during gestation, and/or to provide a prolonged glycemic response during exercise. The methods are based upon the discovery that gamma-cyclodextrins are rapidly metabolized and absorbed in the small intestine, but subsequently result in a surprisingly blunted postprandial glycemic response and reduced insulin secretion.

A method of lowering blood cholesterol in a non-diabetic patient by at least 30% is described. The method involves orally administering for 30 consecutive days a fenugreek seed extract composition. Various methods of preparation and various formulations are described. Physiologically effective pharmaceutical compositions and beverages containing fenugreek seed extracts and other active components are also disclosed.

Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. Coxsackie virus has been detected in human pancreatic beta cells and causes insulitis. This non-destructive islet inflammation does not itself cause diabetes, but this disease will occur if viral infection is followed by a separate autoimmune response. The insulitis is mediated mainly by natural killer cells. Islets from coxsackie virus positive samples displayed reduced insulin secretion in response to glucose and other secretagogues. Virus extracted from positive islets was able to infect beta cells from human islets of non-diabetic donors, causing viral inclusions and signs of pyknosis.

Methods are provided for lowering plasma level of HbA1c in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease and slowing or delaying the development of or worsening of hyperglycemia in a diabetic, pre-diabetic, or non-diabetic patient.

Embodiments of the present invention include methods for the treatment, prevention, or amelioration of vascular disease in diabetic patients. The methods include both implantation of a stent including a first drug. Some embodiments include additional therapy, such as the co-administration of another drug. Some embodiments involve different stent selection for a diabetic patient compared to a non-diabetic patient.

The ophthalmic composition of this invention are used for treatment of diabetic corneal lesion and/or for treatment of deteriorated corneal esthesia, which comprises, as an active ingredient, a compound represented by the general formula (I):whereinA and B are independently lower alkylene,X, Y, and Z are independently halogen,or a pharmacologically acceptable salt thereof.In addition, the ophthalmic composition of this invention are used for treatment of non-diabetic corneal lesion, for treatment of dry eye syndrome, and/or for treatment of hypolacrimation which comprises, as an active ingredient, an aldose reductase inhibitor.The ophthalmic compositions of this invention are effective for treatment of at least one disease selected among corneal lesion, deteriorated corneal esthesia, dry eye syndrome, and hypolacrimation.

The invention is directed to a method of prophylactically or therapeutically treating an animal for vascular leakage in an eye. The method comprises administering to an animal in need thereof an expression vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) such that vascular leakage in the eye of the animal is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating an animal for vascular leakage in an eye. The method comprises periocularly administering to an animal in need thereof PEDF such that vascular leakage of the animal is treated prophylactically or therapeutically. The invention also provides a method of prophylactically or therapeutically treating an animal for non-diabetic vascular leakage in an eye. The method comprises administering to an animal in need thereof PEDF such that non-diabetic vascular leakage in the eye is treated prophylactically or therapeutically.

A therapeutic or an edible composition comprising at least three of the five herbs selected from Prunus amygdales, Ocimum sanctum, Azadirachta indica, Aegle marelose and Vitus vinefera, is provided for the treatment of hyperglycemia, especially for non-insulin dependent diabetic subjects, and the herbal composition has significantly reduced the blood glucose levels in both diabetic and non-diabetic experimental subjects having elevated blood glucose levels.

In an embodiment of the present invention, a nutraceutical formula comprising a combination of chromium, zinc, berry extract, Polygonum cuspidatum extract, aloe vera, chlorophyll and L-arginine combined synergistically to reduce inflammation in mammals suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a of zinc, chromium, berry extract, Polygonum cuspidatum extract, aloe vera, chlorophyll and L-arginine combined synergistically to enhance wound healing in mammals suffering from diabetes. In an alternative embodiment of the present invention, a nutraceutical formula comprising a of zinc, chromium, berry extract, Polygonum cuspidatum extractive, aloe vera, chlorophyll and L-arginine combined synergistically to reduce inflammation in mammals not suffering from diabetes. In another embodiment of the present invention, a nutraceutical formula comprising a combination of zinc, chromium, berry extract, Polygonum cuspidatum extractive, aloe vera, chlorophyll, and L-arginine combined synergistically to enhance wound healing in mammals not suffering from diabetes.